ATC code none PubChem CID 153999 ChemSpider 135727 Molar mass 468.546 g/mol | CAS Number 169939-94-0 IUPHAR/BPS 5263 UNII 721809WQCP | |
 | ||
Ruboxistaurin (proposed brand name Arxxant) is an investigational drug for diabetic retinopathy being investigated by Eli Lilly and Company. It is a member of the bisindolylmaleimide family.
On February 2006, Lilly submitted a New Drug Application for ruboxistaurin, and on August 18, 2006, Lilly received an "approvable" letter from the US FDA for ruboxistaurin, with a request for an additional clinical trial, which would take 5 years to complete.
Mechanism of action
Ruboxistaurin is an inhibitor of protein kinase C-beta.
References
Ruboxistaurin Wikipedia(Text) CC BY-SA